Biological activity of A-289099: An orally active tubulin-binding indolyloxazoline derivative

Molecular Cancer Therapeutics

Volumn 2, Issue 3, 2003, Pages 227-233

  Tahir, Stephen K ^a   Nukkala, Michael A ^a   Zielinski Mozny, Nicolette A ^a   Credo, R Bruce ^a   Warner, Robert B ^a   Li, Qun ^a   Woods, Keith W ^a   Claiborne, Akiyo ^a   Gwaltney II, Stephen L ^a   Frost, David J ^a   Sham, Hing L ^a   Rosenberg, Saul H ^a   Ng, Shi Chung ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 289099; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; CASPASE 3; CELL CYCLE PROTEIN; COLCHICINE; INDOLE DERIVATIVE; OXAZOLE DERIVATIVE; PACLITAXEL; TUBULIN; VINCRISTINE;

ANIMAL; APOPTOSIS; ARTICLE; BINDING SITE; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; MITOSIS; MOUSE; NICK END LABELING; ORAL DRUG ADMINISTRATION; PATHOLOGY; SARCOMA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CASPASE 3; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IN SITU NICK-END LABELING; INDOLES; MICE; MICE, INBRED C57BL; MITOSIS; OXAZOLES; PACLITAXEL; SARCOMA, EXPERIMENTAL; TUBULIN; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0642272506     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tahir, S. K., Trogadis, J. E., Stevens, J. K., and Zimmerman, A. M. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem. Cell Biol., 70: 1159-1173, 1992.
2. Wilson, R. G., Jr., Tahir, S. K., Mechoulam, R., Zimmerman, S., and Zimmerman, A. M. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol. Int., 20: 147-157, 1996. (Pubitemid 26132260)
3. Hamel, E. Antimitotic natural products and their interactions with tubulin. Biochemistry, 16: 207-231, 1996. (Pubitemid 26099989)
4. Jordan, M. A., Hadfield, J. A., Lawrence, N. J., and McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev., 18: 259-296, 1998. (Pubitemid 28346389)
5. Lehnert, M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer, 32A: 912-920, 1996.
6. Germann, U. A. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer, 32A: 927-944, 1996.
7. Ranganathan, S., Benetatos, C. A., Colarusso, P. J., Dexter, D. W., and Hudes, G. R. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer, 77: 562-566, 1998. (Pubitemid 28059462)
8. Han, E. K-H., Gehrke, L., Tahir, S. K., Credo, R. B., Cherian, S. P., Sham, H., Rosenberg, S. H., and Ng, S-C. Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur. J. Can., 36: 1565-1571, 2000. (Pubitemid 30619010)
9. Li, Q., Sham, H., and Rosenberg, S. Antimitotic agents. Annu. Rep. Med. Chem., 34: 139-148, 1999.
10. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N., and Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res., 57: 3208-3213, 1997. (Pubitemid 27351737)
11. Griggs, J., Metcalfe, J. C., and Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol, 2: 82-87, 2001. (Pubitemid 33585919)
12. Tahir, S. K., Han, E. K-H., Credo, B., Jae, H-S., Pietenpol, J. A., Scatena, C. D., Wu-Wong, J. R., Frost, D., Sham, H., Rosenberg, S. H., and Ng, S-C. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res., 61: 5480-5485, 2001. (Pubitemid 32694930)
13. Wu-Wong, J. R., Alder, J. D., Alder, L., Burns, D. J., Han, E. K., Credo, B., Tahir, S. K., Dayton, B. D., Ewing, P. J., and Chiou, W. J. Identification and characterization of A-105972, an antineoplastic agent. Cancer Res., 61: 1486-1492, 2001. (Pubitemid 34292577)
14. Li, Q., Woods, K. W., Claiborne, A., Gwaltney, S. L. II., Barr, K. J., Liu, G., Gehrke, L., Credo, R. B., Hui, Y. H., Lee, J., Warner, R. B., Kovar, P., Nukkala, M. A., Zielinski, N. A., Tahir, S. K., Fitzgerald, M., Kim, K. H., March, K., Frost, D., Ng, S-C., Rosenberg, S., and Sham, H. L. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg. Med. Chem. Lett., 12: 465-469, 2002. (Pubitemid 34113926)
15. Szczepankiewicz, B. G., Liu, G., Jae, H. S., Tasker, A. S., Gunawardana, I. W., von Geldern, T. W., Gwaltney, S. L., II, Wu-Wong, J. R., Gehrke, L., Chiou, W. J., Credo, R. B., Alder, J. D., Nukkala, M. A., Zielinski, N. A., Jarvis, K., Mollison, K. W., Frost, D. J., Bauch, J. L., Hui, Y. H., Claiborne, A. K., Li, Q., and Rosenberg, S. H. New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. J. Med. Chem., 44: 4416-4430, 2001. (Pubitemid 33131666)
16. Tahir, S. K., Kovar, P., Rosenberg, S., and Ng, S-C. A rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques, 29: 156-160, 2000. (Pubitemid 30439429)
17. 50) of an enzymatic reaction. Biochem. Pharmacol., 22:3099-3108, 1973.
18. Armstrong, R. C., Aja, T. J., Hoang, K. D., Gaur, S., Bai, X., Alnemri, E. S., Litwack, G., Karanewsky, D. S., Fritz, L. C., and Tomaselli, K. J. Activation of the CED3/ICE-related protease CPP32 in cerebellar granule neurons undergoing apoptosis but not necrosis. J. Neurosci., 17: 553-562, 1997. (Pubitemid 27024568)
19. Kavallaris, M., Verrills, N. M., and Hill, B. T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Upd., 4: 392-401, 2001. (Pubitemid 34746873)
20. Sorger, P. K., Dobles, M., Tournebize, R., and Hyman, A. A. Coupling cell division and cell death to microtubule dynamics. Curr. Opin. Cell Biol., 9: 807-814, 1997. (Pubitemid 27517269)
21. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., and Pietenpol, J. A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem., 273: 30777-30784, 1998. (Pubitemid 28545562)
22. Fan, W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol., 57: 1215-1221, 1999. (Pubitemid 29186467)
23. Mattern, J., Bak, M., and Volm, M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev., 7: 263-284, 1988.
24. Goldin, A., Vendditti, J. M., Macdonald, J. S., Muggia, F. M., Henney, J. E., and Devita, V. T. Current results of the screening of cancer treatment, National Cancer Institute. Eur. J. Cancer, 17: 129-143, 1980.
25. Chaplin, D. J., Pettit, G. R., Parkins, C. S., and Hill, S. A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer, 74: S86-S88, 1996. (Pubitemid 26237935)
26. Kerbel, R. S., Viloria-Petit, A., Klement, G., and Rak, J. "Accidental" anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer, 36: 1248-1257, 2000. (Pubitemid 30407012)